Document_And_Entity_Informatio
Document And Entity Information | 3 Months Ended | |
Mar. 31, 2014 | Apr. 30, 2014 | |
Document Information [Line Items] | ' | ' |
Entity Registrant Name | 'ENDOCYTE INC | ' |
Entity Central Index Key | '0001235007 | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Filer Category | 'Accelerated Filer | ' |
Trading Symbol | 'ECYT | ' |
Entity Common Stock, Shares Outstanding | ' | 41,504,778 |
Document Type | '10-Q | ' |
Amendment Flag | 'false | ' |
Document Period End Date | 31-Mar-14 | ' |
Document Fiscal Period Focus | 'Q1 | ' |
Document Fiscal Year Focus | '2014 | ' |
CONDENSED_CONSOLIDATED_BALANCE
CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
Current assets: | ' | ' |
Cash and cash equivalents | $32,854,940 | $52,846,940 |
Short-term investments | 91,318,737 | 70,434,148 |
Receivables | 5,354,334 | 6,353,180 |
Prepaid expenses | 4,552,488 | 3,200,924 |
Other assets | 953,607 | 496,338 |
Total current assets | 135,034,106 | 133,331,530 |
Long-term investments | 7,370,093 | 25,571,659 |
Property and equipment, net | 3,856,117 | 3,839,426 |
Other noncurrent assets | 219,563 | 114,961 |
Total assets | 146,479,879 | 162,857,576 |
Current liabilities: | ' | ' |
Accounts payable | 3,665,307 | 5,435,473 |
Accrued wages and benefits | 1,663,316 | 3,065,905 |
Accrued clinical trial expenses | 3,932,758 | 3,728,015 |
Accrued expenses | 2,709,418 | 1,668,944 |
Deferred revenue | 45,733,922 | 59,746,952 |
Current portion of other liabilities | 18,225 | 18,168 |
Total current liabilities | 57,722,946 | 73,663,457 |
Other liabilities, net of current portion | 29,545 | 33,458 |
Deferred revenue, net of current portion | 919,440 | 931,940 |
Total liabilities | 58,671,931 | 74,628,855 |
Stockholders' equity: | ' | ' |
Common stock: $0.001 par value, 100,000,000 shares authorized; 36,155,509 and 36,302,600 shares issued and outstanding at December 31, 2013 and March 31, 2014 | 36,303 | 36,156 |
Additional paid-in capital | 264,789,476 | 262,060,590 |
Accumulated other comprehensive income | 48,344 | 56,691 |
Retained deficit | -177,066,175 | -173,924,716 |
Total stockholders' equity | 87,807,948 | 88,228,721 |
Total liabilities and stockholders' equity | $146,479,879 | $162,857,576 |
CONDENSED_CONSOLIDATED_BALANCE1
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 |
Common stock, par value (in dollars per share) | $0.00 | $0.00 |
Common stock, shares authorized | 100,000,000 | 100,000,000 |
Common stock, shares issued | 36,302,600 | 36,155,509 |
Common stock, shares outstanding | 36,302,600 | 36,155,509 |
CONDENSED_CONSOLIDATED_STATEME
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Revenue: | ' | ' |
Collaboration revenue | $17,268,651 | $14,514,144 |
Total revenue | 17,268,651 | 14,514,144 |
Operating expenses: | ' | ' |
Research and development | 12,986,763 | 12,258,639 |
General and administrative | 7,501,394 | 6,256,002 |
Total operating expenses | 20,488,157 | 18,514,641 |
Loss from operations | -3,219,506 | -4,000,497 |
Other income (expense), net: | ' | ' |
Interest income | 84,688 | 139,736 |
Interest expense | -384 | -774 |
Other income (expense), net | -6,257 | -136 |
Net loss | -3,141,459 | -3,861,671 |
Net loss per share - basic and diluted (in dollars per share) | ($0.09) | ($0.11) |
Items included in other comprehensive loss: | ' | ' |
Unrealized gain on foreign currency translation | 510 | 630 |
Unrealized loss on available-for-sale securities | -8,857 | -40,214 |
Other comprehensive (loss) | -8,347 | -39,584 |
Comprehensive loss | ($3,149,806) | ($3,901,255) |
Weighted-average number of common shares used in net loss per share calculation - basic and diluted (in shares) | 36,193,942 | 35,930,265 |
CONDENSED_CONSOLIDATED_STATEME1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (USD $) | Total | Common Stock [Member] | Additional Paid-in Capital [Member] | Accumulated Other Comprehensive Income (Loss) [Member] | Retained Earnings [Member] |
Balances at Dec. 31, 2013 | $88,228,721 | $36,156 | $262,060,590 | $56,691 | ($173,924,716) |
Balances (in shares) at Dec. 31, 2013 | ' | 36,155,509 | ' | ' | ' |
Exercise of stock options | 481,209 | 147 | 481,062 | 0 | 0 |
Exercise of stock options (in shares) | ' | 147,091 | ' | ' | ' |
Stock-based compensation | 2,182,211 | 0 | 2,182,211 | 0 | 0 |
Employee stock purchase plan | 65,613 | 0 | 65,613 | ' | ' |
Net loss | -3,141,459 | 0 | 0 | 0 | -3,141,459 |
Unrealized gain on foreign currency translation | 510 | 0 | 0 | 510 | 0 |
Unrealized loss on securities | -8,857 | 0 | 0 | -8,857 | 0 |
Balances (unaudited) at Mar. 31, 2014 | $87,807,948 | $36,303 | $264,789,476 | $48,344 | ($177,066,175) |
Balances (unaudited) (in shares) at Mar. 31, 2014 | ' | 36,302,600 | ' | ' | ' |
CONDENSED_CONSOLIDATED_STATEME2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Operating activities | ' | ' |
Net loss | ($3,141,459) | ($3,861,671) |
Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ' | ' |
Depreciation | 201,600 | 144,406 |
Stock-based compensation | 2,247,824 | 1,145,454 |
Accretion of bond premium | 341,243 | 277,402 |
Non cash interest expense | 0 | 0 |
Loss on disposal of property and equipment | 2,619 | 0 |
Change in operating assets and liabilities: | ' | ' |
Receivables | 126,748 | 1,559,178 |
Prepaid expenses and other assets | -1,330,669 | -60,362 |
Accounts payable | -1,555,926 | -1,622,135 |
Accrued interest, wages, benefits and other liabilities | -306,429 | 212,474 |
Deferred revenue | -13,170,993 | -12,998,096 |
Net cash used in operating activities | -16,585,442 | -15,203,350 |
Investing activities | ' | ' |
Purchases of property and equipment | -665,829 | -77,607 |
Purchases of investments | -15,073,013 | -53,886,316 |
Proceeds from sale of investments | 12,039,890 | 71,080,711 |
Net cash provided by (used in) investing activities | -3,698,952 | 17,116,788 |
Financing activities | ' | ' |
Proceeds from the exercise of stock options | 291,884 | 121,791 |
Net cash provided by financing activities | 291,884 | 121,791 |
Effect of exchange rate | 510 | 630 |
Net increase (decrease) in cash and cash equivalents | -19,992,000 | 2,035,859 |
Cash and cash equivalents at beginning of period | 52,846,940 | 33,996,866 |
Cash and cash equivalents at end of period | $32,854,940 | $36,032,725 |
Nature_of_Business_and_Organiz
Nature of Business and Organization | 3 Months Ended |
Mar. 31, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | ' |
1. Nature of Business and Organization | |
Endocyte, Inc. (the “Company”) is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The Company uses its proprietary technology to create novel small molecule drug conjugates (“SMDCs”), and companion imaging agents. The SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with a highly active drug at greater doses, delivered more frequently, and over longer periods of time than would be possible with the untargeted drug alone. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. | |
The Company has two wholly-owned subsidiaries, Endocyte Europe B.V. and Endocyte Europe GmbH, which have been formed to assist with the administration of the pending applications with the European Commission (“EC”) and commercial pre-launch activities in Europe. | |
Significant_Accounting_Policie
Significant Accounting Policies | 3 Months Ended | |||||||
Mar. 31, 2014 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Significant Accounting Policies [Text Block] | ' | |||||||
2. Significant Accounting Policies | ||||||||
Basis of Presentation | ||||||||
The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission. | ||||||||
Segment Information | ||||||||
Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company is performing clinical trials globally and has established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial launch activities in Europe. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment. | ||||||||
Use of Estimates | ||||||||
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates. | ||||||||
Cash and Cash Equivalents | ||||||||
The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager. | ||||||||
Investments | ||||||||
Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security. | ||||||||
Revenue Recognition | ||||||||
The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. | ||||||||
Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered. | ||||||||
In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. | ||||||||
Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone. | ||||||||
Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned. | ||||||||
Research and Development Expenses | ||||||||
Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. | ||||||||
Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of March 31, 2014, the Company had approximately $3.7 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets. | ||||||||
Stock-Based Compensation | ||||||||
The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value, or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued performance-based restricted stock units (“PRSUs”) for which stock-based compensation expense will be recognized when the Company determines that it is probable that the performance conditions will be achieved. The Company has also issued service-based restricted stock units (“RSUs”) for which stock-based compensation expense is recognized ratably over the service period. The Company used the calculated value method to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718. | ||||||||
Net Loss Per Share | ||||||||
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs and RSUs are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. | ||||||||
The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three months ended March 31, 2013 and 2014. | ||||||||
Historical net loss per share | ||||||||
Three Months Ended March 31, | ||||||||
2013 | 2014 | |||||||
Numerator: | ||||||||
Net loss | $ | -3,861,671 | $ | -3,141,459 | ||||
Denominator: | ||||||||
Weighted-average common shares outstanding | 35,930,265 | 36,193,942 | ||||||
Basic and diluted net loss per share | $ | -0.11 | $ | -0.09 | ||||
Common stock equivalents | ||||||||
As of March 31, 2013 and 2014, the following number of potential common stock equivalents were outstanding: | ||||||||
As of March 31, | ||||||||
2013 | 2014 | |||||||
Outstanding common stock options | 4,962,887 | 5,939,710 | ||||||
Outstanding warrants | 133,968 | 34,647 | ||||||
Outstanding PRSUs | 272,750 | 270,649 | ||||||
Outstanding RSUs | — | 196,710 | ||||||
Total | 5,369,605 | 6,441,716 | ||||||
These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings. | ||||||||
New_Accounting_Pronouncements
New Accounting Pronouncements | 3 Months Ended |
Mar. 31, 2014 | |
Accounting Changes and Error Corrections [Abstract] | ' |
Accounting Changes and Error Corrections [Text Block] | ' |
3. New Accounting Pronouncements | |
Recently Adopted Accounting Standards | |
In July 2013, the FASB issued ASU No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists, an update to ASC Topic 740, Income Taxes. This amendment provides clarification regarding the presentation of an unrecognized tax benefit related to a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. Under this new standard, the liability related to an unrecognized tax benefit, or a portion thereof, should be presented in the financial statements as a reduction to a deferred tax asset if available under the tax law of the applicable jurisdiction to settle any additional income taxes that would result from the disallowance of a tax position. Otherwise, the unrecognized tax benefit should be presented in the financial statements as a separate liability. The assessment is based on the unrecognized tax benefit and deferred tax asset that exist at the reporting date. The provisions of the new standard were effective on a prospective basis beginning in 2014 for annual and interim reporting periods. This update became effective for the Company beginning January 1, 2014. The adoption did not have a material impact on the Company’s interim consolidated financial statements. | |
Other_Comprehensive_Income_Los
Other Comprehensive Income (Loss) | 3 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Other Comprehensive Income (Loss), Tax [Abstract] | ' | ||||||||||
Other Comprehensive Income (Loss) [Text Block] | ' | ||||||||||
4. Other Comprehensive Income (Loss) | |||||||||||
The accumulated balances related to each component of other comprehensive income (loss) were as follows: | |||||||||||
Foreign Currency | Unrealized Net | Accumulated Other Comprehensive | |||||||||
Translation Gains | Gains (Losses) | Income (Loss) | |||||||||
(Losses) | on Securities | ||||||||||
Balance at December 31, 2013 | $ | -11,816 | $ | 68,507 | $ | 56,691 | |||||
Unrealized gain (loss) | 510 | -8,857 | -8,347 | ||||||||
Net amount reclassified to net loss | — | — | — | ||||||||
Other comprehensive income (loss) | 510 | -8,857 | -8,347 | ||||||||
Balance at March 31, 2014 | $ | -11,306 | 59,650 | 48,344 | |||||||
The assets and liabilities of foreign operations are translated into U.S. dollars using the current exchange rate. For those operations, changes in exchange rates generally do not affect cash flows, which results in translation adjustments being made in stockholders’ equity rather than to net loss. | |||||||||||
For the three months ended March 31, 2014, there were no amounts reclassified out of Accumulated Other Comprehensive Income. | |||||||||||
Investments
Investments | 3 Months Ended | |||||||||||||
Mar. 31, 2014 | ||||||||||||||
Investments, Debt and Equity Securities [Abstract] | ' | |||||||||||||
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] | ' | |||||||||||||
5. Investments | ||||||||||||||
The Company applies the fair value measurement and disclosure provisions of ASC Topic 820, Fair Value Measurements and Disclosures (“ASC 820”). ASC 820, which defines fair value, establishes a framework for measuring fair value in GAAP, and expands disclosures about fair value measurements. Investments consist primarily of investments with original maturities greater than three months, but no longer than 24 months when purchased. | ||||||||||||||
ASC 820 establishes a three-level valuation hierarchy for fair value measurements. These valuation techniques are based upon the transparency of inputs (observable and unobservable) to the valuation of an asset or liability as of the measurement date. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect the Company’s market assumptions. These two types of inputs create the following fair value hierarchy: | ||||||||||||||
Level 1 — Valuation is based on quoted prices for identical assets or liabilities in active markets. | ||||||||||||||
Level 2 — Valuation is based on quoted prices for similar assets or liabilities in active markets, or other inputs that are observable for the asset or liability, either directly or indirectly, for the full term of the financial instrument. | ||||||||||||||
Level 3 — Valuation is based upon other unobservable inputs that are significant to the fair value measurement. | ||||||||||||||
The fair value of the Company’s fixed income securities is based on a market approach using quoted market values. | ||||||||||||||
The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2013: | ||||||||||||||
Description | Cost | Level 1 | Level 2 | Fair Value (Carrying Value) | ||||||||||
Cash | ||||||||||||||
Cash | $ | 7,887,502 | $ | 7,887,502 | $ | — | $ | 7,887,502 | ||||||
Cash equivalents | ||||||||||||||
Money market funds | 44,959,438 | 44,959,438 | — | 44,959,438 | ||||||||||
Cash and cash equivalents | $ | 52,846,940 | $ | 52,846,940 | $ | — | $ | 52,846,940 | ||||||
Short-term investments (due within 1 year) | ||||||||||||||
U.S. government treasury obligations | $ | 5,009,194 | $ | 5,013,850 | $ | — | $ | 5,013,850 | ||||||
U.S. government agency obligations | 33,598,370 | 33,609,886 | — | 33,609,886 | ||||||||||
Corporate obligations | 31,789,117 | — | 31,810,412 | 31,810,412 | ||||||||||
Total short-term investments | $ | 70,396,681 | $ | 38,623,736 | $ | 31,810,412 | $ | 70,434,148 | ||||||
Long-term investments (due after 1 year through 2 years) | ||||||||||||||
U.S. government agency obligations | $ | 14,807,642 | $ | 14,821,065 | $ | — | $ | 14,821,065 | ||||||
Corporate obligations | 10,743,707 | — | 10,750,594 | 10,750,594 | ||||||||||
Total long-term investments | $ | 25,551,349 | $ | 14,821,065 | $ | 10,750,594 | $ | 25,571,659 | ||||||
The following table summarizes the fair value of cash and cash equivalents and investments as of March 31, 2014: | ||||||||||||||
Description | Cost | Level 1 | Level 2 | Fair Value (Carrying Value) | ||||||||||
Cash | ||||||||||||||
Cash | $ | 9,048,029 | $ | 9,048,029 | $ | — | $ | 9,048,029 | ||||||
Cash equivalents | ||||||||||||||
Money market funds | 23,806,911 | 23,806,911 | — | 23,806,911 | ||||||||||
Cash and cash equivalents | $ | 32,854,940 | $ | 32,854,940 | $ | — | $ | 32,854,940 | ||||||
Short-term investments (due within 1 year) | ||||||||||||||
U.S. government treasury obligations | $ | 5,004,745 | $ | 5,008,000 | $ | — | $ | 5,008,000 | ||||||
U.S. government agency obligations | 51,005,003 | 51,021,550 | — | 51,021,550 | ||||||||||
Corporate obligations | 35,256,158 | — | 35,289,187 | 35,289,187 | ||||||||||
Total short-term investments | $ | 91,265,906 | $ | 56,029,550 | $ | 35,289,187 | $ | 91,318,737 | ||||||
Long-term investments (due after 1 year through 2 years) | ||||||||||||||
U.S. government treasury obligations | $ | 2,995,377 | $ | 2,998,140 | $ | — | $ | 2,998,140 | ||||||
U.S. government agency obligations | 1,301,728 | 1,304,173 | — | 1,304,173 | ||||||||||
Corporate obligations | 3,066,168 | — | 3,067,780 | 3,067,780 | ||||||||||
Total long-term investments | $ | 7,363,273 | $ | 4,302,313 | $ | 3,067,780 | $ | 7,370,093 | ||||||
All securities held at December 31, 2013 and March 31, 2014, were classified as available-for-sale as defined by ASC 320. | ||||||||||||||
Total unrealized gross gains were $58,888 and $ 79,258 for the three months ended March 31, 2013 and 2014, respectively. Total unrealized gross losses were $21,342 and $19,608 for the three months ended March 31, 2013 and 2014, respectively. The Company does not consider any of the unrealized losses to be other-than-temporary impairments because the Company has the intent and ability to hold investments until they recover in value. | ||||||||||||||
Collaborations
Collaborations | 3 Months Ended |
Mar. 31, 2014 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | ' |
Collaborative Arrangement Disclosure [Text Block] | ' |
6. Collaborations | |
Merck Collaboration Agreement | |
In April 2012, the Company entered into a worldwide collaboration agreement with Merck Sharp & Dohme Research GmbH, a subsidiary of Merck & Co, Inc. (“Merck”), regarding the development and commercialization of vintafolide. The agreement grants Merck worldwide rights to develop and commercialize vintafolide and the right to use etarfolatide. The Company received a $120.0 million non-refundable upfront payment and a $5.0 million milestone payment in 2012 and is eligible for additional milestone payments of up to $875.0 million based on the successful achievement of development, regulatory and commercialization goals for vintafolide in a total of six different cancer indications. Depending on clinical trial data results, the near-term potential milestones that could be reached are for the commencement of the first Phase 3 clinical trial of vintafolide for the treatment of non-small cell lung cancer (“NCSLC”), and for marketing authorization approval by the EC for vintafolide for the treatment of patients with platinum resistant ovarian cancer (“PROC”). In addition, the collaboration agreement with Merck provides that in the event of regulatory approval and launch of vintafolide, the Company would split U.S. earnings under the collaboration arrangement on a 50/50 basis with Merck and would receive a double-digit percentage royalty on sales of the product in the rest of the world. The Company has retained the right (which it can opt out of) to co-promote vintafolide with Merck in the U.S. and Merck has the exclusive right to promote vintafolide in the rest of the world. The Company is responsible for the majority of funding and completion of the Phase 3 PROCEED clinical trial of vintafolide for the treatment of patients with PROC. The Company is responsible for the execution of the Phase 2b TARGET trial of vintafolide for the treatment of second line NCSLC, which is now substantially complete, pending the receipt of overall survival results. Merck is responsible for the costs of the TARGET trial and for all other development activities and costs and will have all decision rights with respect to the development and commercialization of vintafolide. The Company is responsible for the development, manufacture and commercialization worldwide of etarfolatide. | |
For revenue recognition purposes, the Company viewed the collaboration with Merck as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company evaluated whether the delivered elements under the arrangement have value on a stand-alone basis and whether objective and reliable evidence of fair value of the undelivered element exists. Deliverables that do not meet these criteria are not evaluated separately for the purpose of revenue recognition. For a single unit of accounting, payments received are recognized in a manner consistent with the final deliverable. The Company has determined that the deliverables related to the collaboration with Merck, including the licenses granted to Merck, as well as the Company performance obligations to provide various research and development services, will be accounted for as a single unit of account. This determination was made because the successful development of the therapeutic drug, vintafolide, is dependent on the companion diagnostic, etarfolatide, to select patients who are most likely to receive the most benefit from vintafolide. Given the nature of the combined benefit of the companion diagnostic and the therapeutic drug, the ongoing research and development services to be provided by the Company are essential to the overall arrangement as the Company has significant knowledge and technical know-how that is important to realizing the value of the licenses granted. Subsequent to the inception of the Merck arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. | |
The Company has been recognizing the non-refundable $120.0 million upfront payment, the $5.0 million milestone payment and funding from the research and development services on a straight-line basis over the performance period, which started at the date of execution of the agreement. The Company recognized approximately $17.3 million of collaboration revenue during the three months ended March 31, 2014. Though accounted for as a single unit of account for presentation purposes, the Company has made an allocation of revenue recognized as collaboration revenue between the license and the services. This allocation is based upon the relative selling price of each deliverable. For the three months ended March 31, 2014, license revenue was approximately $13.7 million while research and development services were approximately $3.6 million of the collaboration revenue. | |
The collaboration arrangement with Merck includes milestone payments of approximately $880.0 million. These milestones consist of development milestones of approximately $380.0 million and sales-based milestones of approximately $500.0 million. The development milestones range from $5.0 million to $45.0 million each and are based on the commencement of a new phase of clinical trials for specific indications, filing for approval in the U.S. or major countries in Europe for specific indications and approval in the U.S. and other major countries. The Company evaluated each of these milestone payments and believes that all but one of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met as it must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. The non-substantive milestone is $5.0 million and was received in the fourth quarter of 2012. This milestone payment of $5.0 million is being combined with the other consideration received in the arrangement, being the license and research and development reimbursements, and under the cumulative catch-up approach is being recognized on a straight-line basis. The $500.0 million of sales-based milestones will occur after development milestones are achieved, and the Company will account for these in the same manner as royalties. The sales-based milestones would be achieved if certain sales thresholds are exceeded for worldwide sales of vintafolide and etarfolatide. To date, the products have not been approved and no revenue has been recognized related to the earnings split on U.S sales, development milestones, sales-based milestones or royalties. | |
Merck has the right to terminate the collaboration agreement on 90 days notice. Merck and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. The Company has the right to terminate the agreement in the event that Merck challenges an Endocyte patent right relating to vintafolide. Upon termination of the agreement, depending upon the circumstances, the parties have varying rights and obligations with respect to the continued development and commercialization of vintafolide and, in the case of termination for cause by Merck, certain royalty obligations and U.S. profit and loss sharing. | |
NMP License and Commercialization Agreement | |
In August 2013, the Company entered into a license and commercialization agreement with Nihon Medi-Physic Co., LTD. (“NMP”) that grants NMP the right to develop and commercialize etarfolatide in Japan for use in connection with vintafolide in Japan. The Company received a $1.0 million non-refundable upfront payment, is eligible for up to $4.5 million based on the successful achievement of regulatory goals for etarfolatide in five different cancer indications and is eligible to receive double-digit percentage royalties on sales of etarfolatide in Japan. | |
For revenue recognition purposes, the Company viewed the agreement with NMP as a multiple element arrangement. Multiple element arrangements are analyzed to determine whether the various performance obligations, or elements, can be separated or whether they must be accounted for as a single unit of accounting. The Company has identified the deliverables related to the collaboration with NMP, which include the license granted to NMP, as well as the obligation to provide preclinical and clinical supply of etarfolatide, to provide rights to NMP if a product is developed that replaces etarfolatide, obligation for the Company to provide clinical data to NMP during the contract period and coordination of development and commercialization efforts between Merck for vintafolide and NMP for etarfolatide in Japan. The Company’s deliverables will be accounted for as a single unit of account, therefore the non-refundable upfront payment will be recognized on a straight-line basis over the performance period. This determination was made because the successful development of etarfolatide in Japan requires the ongoing participation by the Company, including coordination with Merck and the development of the related therapeutic drug, vintafolide. The performance period over which the revenue will be recognized continues from the date of execution of the agreement through the end of 2033, the estimated termination date of the contract which is when the Company’s performance obligations will be completed. Any significant changes in the timing of the performance period could result in a change in the revenue recognition period. The Company had deferred revenue related to the agreement of approximately $1.0 million at March 31, 2014. Subsequent to the inception of the NMP arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. | |
The arrangement with NMP includes milestone payments of up to approximately $4.5 million and the milestones are based on the commencement of clinical trials in Japan for specific and non-specific indications and filing for approval in Japan for specific and non-specific indications. The Company evaluated each of these milestone payments and believes that all of the milestones are substantive as there is substantial performance risk that must occur in order for them to be met because the Company must complete additional clinical trials which show a positive outcome or receive approval from a regulatory authority and would be commensurate with the enhancement of value of the underlying intellectual property. To date, the products have not been approved in Japan and no revenue has been recognized related to the regulatory milestones or royalties. | |
NMP has the right to terminate the collaboration agreement on 90 days notice prior to first commercial sale in Japan and six months notice after the first commercial sale in Japan. NMP also has the right to terminate the agreement on six months notice if the Company and/or Merck fail to launch vintafolide after receiving regulatory approval in Japan. NMP and the Company each have the right to terminate the agreement due to the material breach or insolvency of the other party. Upon termination of the agreement depending on the circumstances, the parties have varying rights and obligations with respect to licensing and related regulatory materials and data. | |
Stockholders_Equity_Deficit
Stockholders' Equity (Deficit) | 3 Months Ended | |||||||||||
Mar. 31, 2014 | ||||||||||||
Equity [Abstract] | ' | |||||||||||
Stockholders' Equity Note Disclosure [Text Block] | ' | |||||||||||
7. Stockholders’ Equity (Deficit) | ||||||||||||
Stock-Based Compensation Plans | ||||||||||||
The Company has had stock-based compensation plans since 1997. The awards made under the plans adopted in 1997 and 2007 consisted of stock options. The 2010 Equity Incentive Plan (the “2010 Plan”), which is the only plan under which awards may currently be made, authorizes awards in the form of stock options, stock appreciation rights, restricted stock, PRSUs, performance units and performance shares, and RSUs. Awards under the 2010 Plan may be made to employees, directors and certain consultants as determined by the compensation committee of the board of directors. There were 6,625,563 and 8,071,563 shares of common stock authorized and reserved at December 31, 2013 and March 31, 2014 under these plans, respectively. | ||||||||||||
Stock Options | ||||||||||||
Under the various plans, employees have been granted incentive stock options, while directors and consultants have been granted non-qualified options. The plans allow the holder of an option to purchase common stock at the exercise price, which was at or above the fair value of the Company’s common stock on the date of grant. | ||||||||||||
Generally, options granted under the 1997 and 2007 plans in connection with an employee’s commencement of employment vest over a four-year period with one-half of the shares subject to the grant vesting after two years of employment and remaining options vesting monthly over the remainder of the four-year period. Options granted under the 1997 and 2007 plans for performance or promotions vest monthly over a four-year period. Generally, options granted under the 2010 Plan vest annually over a four-year period. Unexercised stock options terminate on the tenth anniversary date after the date of grant. The Company recognizes the stock-based compensation expense over the requisite service period of the individual grantees, which generally equals the vesting period. The Company utilizes a Black-Scholes option-pricing model to estimate the value of stock options. The Black-Scholes model allows the use of a range of assumptions related to volatility, risk-free interest rate, employee exercise behavior and dividend yield. Prior to 2013, since the Company did not have sufficient history as a publicly traded company to evaluate volatility, the Company used an average of several peer companies’ volatilities to determine a reasonable estimate of volatility. Beginning in 2013, the Company utilizes a combination of peer volatility and company volatility. For purposes of identifying peer companies, the Company considered characteristics such as industry, length of trading history, market capitalization and similar product pipelines. | ||||||||||||
Due to insufficient history as a public company, the Company is using the “simplified” method for “plain vanilla” options to estimate the expected term of the stock options grants. Under this approach, the weighted-average expected life is presumed to be the average of the vesting term and the contractual term of the option. The risk-free interest rate assumption is derived from the weighted-average yield of a Treasury security with the same term as the expected life of the options, and the dividend yield assumption is based on historical experience and the Company’s estimate of future dividend yields. | ||||||||||||
The weighted-average value of the individual options granted during the three months ended March 31, 2013 and 2014 were determined using the following assumptions: | ||||||||||||
Three Months | ||||||||||||
Ended | ||||||||||||
March 31, | ||||||||||||
2013 | 2014 | |||||||||||
Weighted-average volatility | 101 | % | 102 | % | ||||||||
Risk-free interest rate | 1.07 | % | 1.92 | % | ||||||||
Weighted-average expected life (in years) | 6.3 | 6.3 | ||||||||||
Dividend yield | 0 | % | 0 | % | ||||||||
The Company’s stock option activity and related information are summarized as follows: | ||||||||||||
Options | Weighted- | Weighted- | Aggregate | |||||||||
Average | Average | Intrinsic | ||||||||||
Exercise | Remaining | Value | ||||||||||
Price | Contractual | |||||||||||
Term | ||||||||||||
(In Years) | ||||||||||||
Outstanding at January 1, 2014 | 5,246,465 | $ | 6.76 | |||||||||
Granted during period | 856,261 | 11.13 | ||||||||||
Exercised during period | -147,091 | 3.27 | ||||||||||
Expired during period | — | — | ||||||||||
Forfeited during period | -15,925 | 16.42 | ||||||||||
Outstanding at March 31, 2014 | 5,939,710 | $ | 7.45 | 7.6 | $ | 97,181,600 | ||||||
Exercisable at March 31, 2014 | 2,697,802 | $ | 5.1 | 6.2 | $ | 50,465,826 | ||||||
As of March 31, 2014, the total remaining unrecognized compensation cost related to stock options was $20.6 million, which is being amortized over the remaining requisite service period. The expense is expected to be recognized over a weighted average period of 2.0 years. | ||||||||||||
Restricted Stock Units | ||||||||||||
In May 2011, the Company adopted and granted awards under a performance-based RSU program (the “2011 PRSU Program”) under the 2010 Plan. Each unit represents an amount equal to one share of the Company’s common stock. The PRSUs will be earned, in whole or in part, based on performance and service conditions. The performance condition is based upon whether the Company receives regulatory approval to sell a therapeutic product, and the awards include a target number of PRSUs that will vest upon a First Commercial Approval, and a maximum number of PRSUs that will vest upon a Second Commercial Approval. Any earned PRSUs will vest fifty percent based on the performance condition of commercial approval and fifty percent one year thereafter to fulfill the service condition, which requires the employee to remain employed by the Company. | ||||||||||||
As of March 31, 2014, the Company had 270,649 PRSU awards outstanding. The unrecorded stock compensation expense is based on number of units granted, less estimated forfeitures based on the Company’s historical forfeiture rate of 6.49%, and the closing market price of the Company’s common stock at the grant date. As of March 31, 2014, the performance condition of obtaining regulatory approval had not been achieved, therefore, no vesting had occurred. The awards are being accounted for under ASC 718, and compensation expense is to be recorded if the Company determines that it is probable that the performance conditions will be achieved. As of March 31, 2014, it was not probable that the performance conditions will be achieved, therefore, no compensation expense related to the PRSUs was recorded for the three months ended March 31, 2014. Unrecorded compensation expense for the 2011 PRSU program as of March 31, 2014 was $2.7 million. | ||||||||||||
As of March 31, 2014, the Company had 196,710 RSU awards outstanding under the 2010 Plan which were granted during the three months ended March 31, 2014. The RSUs are service-based awards that will vest and be paid in four equal installments annually beginning in February 2015 in the form of one share of the Company’s common stock for each RSU. The awards were granted at a weighted average fair value of $11.11 per share. As of March 31, 2014, the total remaining unrecognized compensation cost related to RSUs was $2.1 million, which is being amortized over the remaining requisite service period, and had a weighted average remaining life of 2.4 years. | ||||||||||||
Income_Taxes
Income Taxes | 3 Months Ended |
Mar. 31, 2014 | |
Income Tax Disclosure [Abstract] | ' |
Income Tax Disclosure [Text Block] | ' |
8. Income Taxes | |
The Company accounts for income taxes under the liability method in accordance with the provisions of ASC Topic 740, Income Taxes. The Company recognizes future tax benefits, such as net operating losses, to the extent those benefits are expected to be realized in future periods. Due to uncertainty surrounding the realization of its deferred tax assets, the Company has recorded an equal and offsetting valuation allowance against its net deferred tax assets. The Company experienced a change in ownership as defined under Section 382 of the U.S. Internal Revenue Code in August 2011. As a result, the future use of its net operating losses and credit equivalents is currently limited to approximately $ 133.2 million for 2014, $ 39.0 million for 2015, $29.7 million for 2016 and $16.8 million for 2017. Any available but unused amounts will become available for use in all successive years. | |
Subsequent_Events
Subsequent Events | 3 Months Ended |
Mar. 31, 2014 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
9. Subsequent Events | |
On April 2, 2014, the Company issued 5,175,000 shares of its common stock in a public offering and received net proceeds of approximately $101.8 million. | |
Following the completion of the pre-specified interim futility analysis of the PROCEED trial, on April 30, 2014, the Data and Safety Monitoring Board (“DSMB”) recommended that the PROCEED trial be stopped because vintafolide did not demonstrate efficacy on the pre-specified outcome of progression free survival (“PFS”). In May 2014, the Company suspended screening and enrollment for the PROCEED trial pending review of the interim data, while continuing to treat patients already participating in the trial. Pending additional review of the PROCEED trial interim data, the EC is not expected to take further action on the pending applications for conditional marketing authorizations in Europe for vintafolide for the treatment of PROC, and etarfolatide and folic acid for patient selection. In the event that the Company decides to terminate the PROCEED trial, the Company would record a charge in the period of termination for the remaining expenses of the trial, including prepaid research and development expenses and site close-out expenses. | |
The Company may accelerate the recognition of the balance of deferred revenue of $45.7 million associated with the Merck collaboration in the second quarter of 2014. This deferred revenue is a combination of a portion of the upfront payment from Merck, a $5.0 million milestone payment and reimbursable services provided by the Company for the development of vintafolide which, through the end of the first quarter of 2014, was being recognized over the performance period. The potential acceleration would be the result of the completion of certain obligations associated with the Merck collaboration agreement, the transfer of knowledge and know-how to Merck and as a result of the completion of the enrollment of the 250th FR(100%) patient (patients in which 100 percent of their target lesions over-expressed the folate receptor as determined by an etarfolatide scan) in the PROCEED trial. If the remaining deferred revenue balance is recognized in the second quarter of 2014, any future reimbursable research and development services will be recognized as revenue in the period in which the services are performed. | |
Significant_Accounting_Policie1
Significant Accounting Policies (Policies) | 3 Months Ended | |||||||
Mar. 31, 2014 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Basis of Accounting, Policy [Policy Text Block] | ' | |||||||
Basis of Presentation | ||||||||
The accompanying condensed consolidated financial statements include the accounts of Endocyte, Inc. and its subsidiaries and all intercompany amounts have been eliminated. The condensed consolidated financial statements are prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) for interim financial information to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring accruals and revisions of estimates, considered necessary for a fair presentation of the accompanying condensed consolidated financial statements have been included. Interim results for the three months ended March 31, 2014 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2014 or any other future period. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013. Subsequent events have been evaluated through the date of issuance, which is the same as the date this Form 10-Q is filed with the Securities and Exchange Commission. | ||||||||
Segment Reporting, Policy [Policy Text Block] | ' | |||||||
Segment Information | ||||||||
Operating segments are defined as components of an enterprise engaging in business activities for which discrete financial information is available and regularly reviewed by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company is performing clinical trials globally and has established a subsidiary in The Netherlands to assist in the administration of filing applications in Europe and a subsidiary in Switzerland for commercial launch activities in Europe. All long-lived assets are held in the U.S. The Company views its operations and manages its business in one operating segment. | ||||||||
Use of Estimates, Policy [Policy Text Block] | ' | |||||||
Use of Estimates | ||||||||
The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual amounts could differ from those estimates. | ||||||||
Cash and Cash Equivalents, Policy [Policy Text Block] | ' | |||||||
Cash and Cash Equivalents | ||||||||
The Company considers cash and all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents consist primarily of money market instruments that are maintained by an investment manager. | ||||||||
Investment, Policy [Policy Text Block] | ' | |||||||
Investments | ||||||||
Investments consist primarily of investments in U.S. Treasuries, U.S. Government agency obligations and corporate debt securities, which could also include commercial paper, that are maintained by an investment manager. Management determines the appropriate classification of marketable securities at the time of purchase and reevaluates such classification as of each balance sheet date. Available-for-sale securities are carried at fair value, with the unrealized gains and losses reported in other comprehensive income. Realized gains and losses and declines in value judged to be other-than-temporary on available-for-sale securities are included in other income. The Company considers and accounts for other-than-temporary impairments according to the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 320, Investments — Debt and Equity Securities (“ASC 320”). The cost of securities sold is based on the specific-identification method. Discounts and premiums on debt securities are amortized to interest income and expense over the term of the security. | ||||||||
Revenue Recognition, Policy [Policy Text Block] | ' | |||||||
Revenue Recognition | ||||||||
The Company recognizes revenues from license and collaboration agreements when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the fee is fixed or determinable, and there is reasonable assurance that the related amounts are collectible in accordance with ASC Topic 605, Revenue Recognition (“ASC 605”). The Company’s license and collaboration agreements may contain multiple elements, including grants of licenses to intellectual property rights, agreement to provide research and development services and other deliverables. The deliverables under such arrangements are evaluated under ASC Subtopic 605-25, Multiple-Element Arrangements. Under ASC 605-25, each required deliverable is evaluated to determine whether it qualifies as a separate unit of accounting based on whether the deliverable has “stand-alone value” to the customer. The arrangement’s consideration that is fixed or determinable, excluding contingent milestone payments, is then allocated to each separate unit of accounting based on the relative selling price of each deliverable. In general, the consideration allocated to each unit of accounting is recognized as the related goods or services are delivered, limited to the consideration that is not contingent upon future deliverables. | ||||||||
Upfront payments for licensing the Company's intellectual property are evaluated to determine if the licensee can obtain stand-alone value from the license separate from the value of the research and development services and other deliverables in the arrangement to be provided by the Company. If at the inception of an arrangement the Company determines that the license does not have stand-alone value separate from the research and development services or other deliverables, the license, services and other deliverables are combined as one unit of account and upfront payments are recorded as deferred revenue in the balance sheet and are recognized in a manner consistent with the final deliverable. Subsequent to the inception of an arrangement, the Company evaluates the remaining deliverables for separation as items in the arrangement are delivered. When stand-alone value is identified, the related consideration is recorded as revenue in the period in which the license or other intellectual property rights are delivered. | ||||||||
In those circumstances where research and development services or other deliverables are combined with the license, and multiple services are being performed such that a common output measure to determine a pattern of performance cannot be discerned, the Company recognizes amounts received on a straight line basis over the performance period. Such amounts are recorded as collaboration revenue. Any subsequent reimbursement payments, which are contingent upon the Company’s future research and development expenditures, will be recorded as collaboration revenue and will be recognized on a straight-line basis over the performance period using the cumulative catch up method. The costs associated with these activities are reflected as a component of research and development expense in the statements of operations in the period incurred. | ||||||||
Milestone payments under collaborative arrangements are triggered either by the results of the Company’s research and development efforts, achievement of regulatory goals or by specified sales results by a third-party collaborator. Milestones related to the Company’s development-based activities may include initiation of various phases of clinical trials and applications and acceptance for product approvals by regulatory agencies. Due to the uncertainty involved in meeting these development-based milestones, the determination is made at the inception of the collaboration agreement whether the development-based milestones are considered to be substantive (i.e. not just achieved through passage of time). In addition, the amounts of the payments assigned thereto are considered to be commensurate with the enhancement of the value of the delivered intellectual property as a result of the Company’s performance. Because the Company’s involvement is necessary to the achievement of development-based milestones, the Company would account for development-based milestones as revenue upon achievement of the substantive milestone events. Milestones related to sales-based activities may be triggered upon events such as first commercial sale of a product or when sales first achieve a defined level. Since these sales-based milestones would be achieved after the completion of the Company’s development activities, the Company would account for the sales-based milestones in the same manner as royalties, with revenue recognized upon achievement of the milestone. | ||||||||
Royalties based on reported sales of licensed products will be recognized based on contract terms when reported sales are reliably measurable and collectability is reasonably assured. To date, none of the Company's products have been approved and therefore the Company has not earned any royalty revenue from product sales. In territories where the Company and the collaborator will share profit, the revenue will be recorded in the period earned. | ||||||||
Research and Development Expense, Policy [Policy Text Block] | ' | |||||||
Research and Development Expenses | ||||||||
Research and development expenses represent costs associated with the ongoing development of SMDCs and companion imaging agents and include salaries, supplies, and expenses for clinical trials. The Company records accruals for clinical trial expenses based on the estimated amount of work completed. The Company monitors patient enrollment levels and related activities to the extent possible through internal reviews, correspondence, and discussions with research organizations. | ||||||||
Upfront payments made in connection with business collaborations and research and development arrangements are evaluated under ASC Subtopic 730-20, Research and Development Arrangements. Upfront payments made in connection with business development collaborations are expensed as research and development costs, as the assets acquired do not have alternative future use. Amounts related to future research and development are capitalized as prepaid research and development and are expensed over the service period based upon the level of services provided. As of March 31, 2014, the Company had approximately $3.7 million of capitalized research and development costs included in prepaid expenses and other noncurrent assets. | ||||||||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | |||||||
Stock-Based Compensation | ||||||||
The Company accounts for its stock options pursuant to ASC Topic 718, Compensation — Stock Compensation (“ASC 718”), which requires the recognition of the fair value, or calculated value for nonpublic entities, of stock-based compensation in net income. Stock-based compensation consists of stock options, which are granted at exercise prices at or above the fair market value of the Company’s common stock on the dates of grant. The Company has issued performance-based restricted stock units (“PRSUs”) for which stock-based compensation expense will be recognized when the Company determines that it is probable that the performance conditions will be achieved. The Company has also issued service-based restricted stock units (“RSUs”) for which stock-based compensation expense is recognized ratably over the service period. The Company used the calculated value method to measure its stock-based compensation prior to its initial public offering. The Company recognizes compensation cost based on the grant-date value estimated in accordance with the provisions of ASC 718. | ||||||||
Earnings Per Share, Policy [Policy Text Block] | ' | |||||||
Net Loss Per Share | ||||||||
Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period determined using the treasury-stock method and the if-converted method. For purposes of this calculation, stock options, warrants, PRSUs and RSUs are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. | ||||||||
The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three months ended March 31, 2013 and 2014. | ||||||||
Historical net loss per share | ||||||||
Three Months Ended March 31, | ||||||||
2013 | 2014 | |||||||
Numerator: | ||||||||
Net loss | $ | -3,861,671 | $ | -3,141,459 | ||||
Denominator: | ||||||||
Weighted-average common shares outstanding | 35,930,265 | 36,193,942 | ||||||
Basic and diluted net loss per share | $ | -0.11 | $ | -0.09 | ||||
Common stock equivalents | ||||||||
As of March 31, 2013 and 2014, the following number of potential common stock equivalents were outstanding: | ||||||||
As of March 31, | ||||||||
2013 | 2014 | |||||||
Outstanding common stock options | 4,962,887 | 5,939,710 | ||||||
Outstanding warrants | 133,968 | 34,647 | ||||||
Outstanding PRSUs | 272,750 | 270,649 | ||||||
Outstanding RSUs | — | 196,710 | ||||||
Total | 5,369,605 | 6,441,716 | ||||||
These common stock equivalents were excluded from the determination of diluted net loss per share due to their anti-dilutive effect on earnings. | ||||||||
Significant_Accounting_Policie2
Significant Accounting Policies (Tables) | 3 Months Ended | |||||||
Mar. 31, 2014 | ||||||||
Accounting Policies [Abstract] | ' | |||||||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | ' | |||||||
The following tables and discussion provide a reconciliation of the numerator and denominator of the basic and diluted net loss per share computations. The calculation below provides net loss, weighted-average common shares outstanding, and the resultant net loss per share on both a basic and diluted basis for the three months ended March 31, 2013 and 2014. | ||||||||
Historical net loss per share | ||||||||
Three Months Ended March 31, | ||||||||
2013 | 2014 | |||||||
Numerator: | ||||||||
Net loss | $ | -3,861,671 | $ | -3,141,459 | ||||
Denominator: | ||||||||
Weighted-average common shares outstanding | 35,930,265 | 36,193,942 | ||||||
Basic and diluted net loss per share | $ | -0.11 | $ | -0.09 | ||||
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | ' | |||||||
As of March 31, 2013 and 2014, the following number of potential common stock equivalents were outstanding: | ||||||||
As of March 31, | ||||||||
2013 | 2014 | |||||||
Outstanding common stock options | 4,962,887 | 5,939,710 | ||||||
Outstanding warrants | 133,968 | 34,647 | ||||||
Outstanding PRSUs | 272,750 | 270,649 | ||||||
Outstanding RSUs | — | 196,710 | ||||||
Total | 5,369,605 | 6,441,716 | ||||||
Other_Comprehensive_Income_Los1
Other Comprehensive Income (Loss) (Tables) | 3 Months Ended | ||||||||||
Mar. 31, 2014 | |||||||||||
Other Comprehensive Income (Loss), Tax [Abstract] | ' | ||||||||||
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | ' | ||||||||||
The accumulated balances related to each component of other comprehensive income (loss) were as follows: | |||||||||||
Foreign Currency | Unrealized Net | Accumulated Other Comprehensive | |||||||||
Translation Gains | Gains (Losses) | Income (Loss) | |||||||||
(Losses) | on Securities | ||||||||||
Balance at December 31, 2013 | $ | -11,816 | $ | 68,507 | $ | 56,691 | |||||
Unrealized gain (loss) | 510 | -8,857 | -8,347 | ||||||||
Net amount reclassified to net loss | — | — | — | ||||||||
Other comprehensive income (loss) | 510 | -8,857 | -8,347 | ||||||||
Balance at March 31, 2014 | $ | -11,306 | 59,650 | 48,344 | |||||||
Investments_Tables
Investments (Tables) | 3 Months Ended | |||||||||||||
Mar. 31, 2014 | ||||||||||||||
Investments, Debt and Equity Securities [Abstract] | ' | |||||||||||||
Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block] | ' | |||||||||||||
The following table summarizes the fair value of cash and cash equivalents and investments as of December 31, 2013: | ||||||||||||||
Description | Cost | Level 1 | Level 2 | Fair Value (Carrying | ||||||||||
Value) | ||||||||||||||
Cash | ||||||||||||||
Cash | $ | 7,887,502 | $ | 7,887,502 | $ | — | $ | 7,887,502 | ||||||
Cash equivalents | ||||||||||||||
Money market funds | 44,959,438 | 44,959,438 | — | 44,959,438 | ||||||||||
Cash and cash equivalents | $ | 52,846,940 | $ | 52,846,940 | $ | — | $ | 52,846,940 | ||||||
Short-term investments (due within 1 year) | ||||||||||||||
U.S. government treasury obligations | $ | 5,009,194 | $ | 5,013,850 | $ | — | $ | 5,013,850 | ||||||
U.S. government agency obligations | 33,598,370 | 33,609,886 | — | 33,609,886 | ||||||||||
Corporate obligations | 31,789,117 | — | 31,810,412 | 31,810,412 | ||||||||||
Total short-term investments | $ | 70,396,681 | $ | 38,623,736 | $ | 31,810,412 | $ | 70,434,148 | ||||||
Long-term investments (due after 1 year through 2 years) | ||||||||||||||
U.S. government agency obligations | $ | 14,807,642 | $ | 14,821,065 | $ | — | $ | 14,821,065 | ||||||
Corporate obligations | 10,743,707 | — | 10,750,594 | 10,750,594 | ||||||||||
Total long-term investments | $ | 25,551,349 | $ | 14,821,065 | $ | 10,750,594 | $ | 25,571,659 | ||||||
The following table summarizes the fair value of cash and cash equivalents and investments as of March 31, 2014: | ||||||||||||||
Description | Cost | Level 1 | Level 2 | Fair Value (Carrying | ||||||||||
Value) | ||||||||||||||
Cash | ||||||||||||||
Cash | $ | 9,048,029 | $ | 9,048,029 | $ | — | $ | 9,048,029 | ||||||
Cash equivalents | ||||||||||||||
Money market funds | 23,806,911 | 23,806,911 | — | 23,806,911 | ||||||||||
Cash and cash equivalents | $ | 32,854,940 | $ | 32,854,940 | $ | — | $ | 32,854,940 | ||||||
Short-term investments (due within 1 year) | ||||||||||||||
U.S. government treasury obligations | $ | 5,004,745 | $ | 5,008,000 | $ | — | $ | 5,008,000 | ||||||
U.S. government agency obligations | 51,005,003 | 51,021,550 | — | 51,021,550 | ||||||||||
Corporate obligations | 35,256,158 | — | 35,289,187 | 35,289,187 | ||||||||||
Total short-term investments | $ | 91,265,906 | $ | 56,029,550 | $ | 35,289,187 | $ | 91,318,737 | ||||||
Long-term investments (due after 1 year through 2 years) | ||||||||||||||
U.S. government treasury obligations | $ | 2,995,377 | $ | 2,998,140 | $ | — | $ | 2,998,140 | ||||||
U.S. government agency obligations | 1,301,728 | 1,304,173 | — | 1,304,173 | ||||||||||
Corporate obligations | 3,066,168 | — | 3,067,780 | 3,067,780 | ||||||||||
Total long-term investments | $ | 7,363,273 | $ | 4,302,313 | $ | 3,067,780 | $ | 7,370,093 | ||||||
Stockholders_Equity_Deficit_Ta
Stockholders' Equity (Deficit) (Tables) | 3 Months Ended | |||||||||||
Mar. 31, 2014 | ||||||||||||
Equity [Abstract] | ' | |||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | ' | |||||||||||
The weighted-average value of the individual options granted during the three months ended March 31, 2013 and 2014 were determined using the following assumptions: | ||||||||||||
Three Months | ||||||||||||
Ended | ||||||||||||
March 31, | ||||||||||||
2013 | 2014 | |||||||||||
Weighted-average volatility | 101 | % | 102 | % | ||||||||
Risk-free interest rate | 1.07 | % | 1.92 | % | ||||||||
Weighted-average expected life (in years) | 6.3 | 6.3 | ||||||||||
Dividend yield | 0 | % | 0 | % | ||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||
The Company’s stock option activity and related information are summarized as follows: | ||||||||||||
Options | Weighted- | Weighted- | Aggregate | |||||||||
Average | Average | Intrinsic | ||||||||||
Exercise | Remaining | Value | ||||||||||
Price | Contractual | |||||||||||
Term | ||||||||||||
(In Years) | ||||||||||||
Outstanding at January 1, 2014 | 5,246,465 | $ | 6.76 | |||||||||
Granted during period | 856,261 | 11.13 | ||||||||||
Exercised during period | -147,091 | 3.27 | ||||||||||
Expired during period | — | — | ||||||||||
Forfeited during period | -15,925 | 16.42 | ||||||||||
Outstanding at March 31, 2014 | 5,939,710 | $ | 7.45 | 7.6 | $ | 97,181,600 | ||||||
Exercisable at March 31, 2014 | 2,697,802 | $ | 5.1 | 6.2 | $ | 50,465,826 | ||||||
Significant_Accounting_Policie3
Significant Accounting Policies (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Numerator: | ' | ' |
Net loss | ($3,141,459) | ($3,861,671) |
Denominator: | ' | ' |
Weighted-average common shares outstanding (in shares) | 36,193,942 | 35,930,265 |
Basic and diluted net loss per share (in dollars per share) | ($0.09) | ($0.11) |
Significant_Accounting_Policie4
Significant Accounting Policies (Details 1) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Potential Common Stock Equivalents, Outstanding | 6,441,716 | 5,369,605 |
Outstanding Common Stock Options [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Potential Common Stock Equivalents, Outstanding | 5,939,710 | 4,962,887 |
Outstanding PRSUs [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Potential Common Stock Equivalents, Outstanding | 270,649 | 272,750 |
Outstanding RSUs [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Potential Common Stock Equivalents, Outstanding | 196,710 | 0 |
Outstanding warrants [Member] | ' | ' |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ' | ' |
Potential Common Stock Equivalents, Outstanding | 34,647 | 133,968 |
Significant_Accounting_Policie5
Significant Accounting Policies (Details Textual) (Research and Development Arrangement [Member], USD $) | Mar. 31, 2014 |
In Millions, unless otherwise specified | |
Research and Development Arrangement [Member] | ' |
Significant Accounting Policies [Line Items] | ' |
Prepaid Expense and Other Assets | $3.70 |
Other_Comprehensive_Income_Los2
Other Comprehensive Income (Loss) (Details) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Other Comprehensive Income Loss [Line Items] | ' | ' |
Foreign Currency Translation Gains (Losses), Beginning balance | ($11,816) | ' |
Foreign Currency Translation Gains (Losses), Unrealized gain (loss) | 510 | 630 |
Foreign Currency Translation Gains (Losses), Net amount reclassified to net loss | 0 | ' |
Foreign Currency Translation Gains (Losses), Other comprehensive income (loss) | 510 | ' |
Foreign Currency Translation Gains (Losses), Ending balance | -11,306 | ' |
Unrealized Net Gains (Losses) on Securities, Beginning balance | 68,507 | ' |
Unrealized Net Gains (Losses) on Securities, Unrealized gain (loss) | -8,857 | ' |
Unrealized Net Gains (Losses) on Securities, Net amount reclassified to net loss | 0 | ' |
Unrealized Net Gains (Losses) on Securities, Other comprehensive income (loss) | -8,857 | -40,214 |
Unrealized Net Gains (Losses) on Securities, Ending balance | 59,650 | ' |
Accumulated Other Comprehensive Income (Loss), Beginning balance | 56,691 | ' |
Accumulated Other Comprehensive Income (Loss), Unrealized gain (loss) | -8,347 | ' |
Accumulated Other Comprehensive Income (Loss), Net amount reclassified to net loss | 0 | ' |
Accumulated Other Comprehensive Income (Loss), Income comprehensive income (loss) | -8,347 | ' |
Accumulated Other Comprehensive Income (Loss), Ending balance | $48,344 | ' |
Investments_Details
Investments (Details) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Mar. 31, 2013 | Dec. 31, 2012 |
Cash | ' | ' | ' | ' |
Cash | $9,048,029 | $7,887,502 | ' | ' |
Cash equivalents | ' | ' | ' | ' |
Money market funds | 23,806,911 | 44,959,438 | ' | ' |
Cash and cash equivalents | 32,854,940 | 52,846,940 | 36,032,725 | 33,996,866 |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 91,318,737 | 70,434,148 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 7,370,093 | 25,571,659 | ' | ' |
US Treasury Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 5,008,000 | 5,013,850 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 2,998,140 | ' | ' | ' |
US Government Agencies Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 51,021,550 | 33,609,886 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 1,304,173 | 14,821,065 | ' | ' |
Corporate Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 35,289,187 | 31,810,412 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 3,067,780 | 10,750,594 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | ' | ' | ' | ' |
Cash | ' | ' | ' | ' |
Cash | 9,048,029 | 7,887,502 | ' | ' |
Cash equivalents | ' | ' | ' | ' |
Money market funds | 23,806,911 | 44,959,438 | ' | ' |
Cash and cash equivalents | 32,854,940 | 52,846,940 | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 56,029,550 | 38,623,736 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 4,302,313 | 14,821,065 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | US Treasury Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 5,008,000 | 5,013,850 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 2,998,140 | ' | ' | ' |
Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 51,021,550 | 33,609,886 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 1,304,173 | 14,821,065 | ' | ' |
Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 0 | 0 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | ' | ' | ' | ' |
Cash | ' | ' | ' | ' |
Cash | 0 | 0 | ' | ' |
Cash equivalents | ' | ' | ' | ' |
Money market funds | 0 | 0 | ' | ' |
Cash and cash equivalents | 0 | 0 | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 35,289,187 | 31,810,412 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 3,067,780 | 10,750,594 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | US Treasury Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 0 | 0 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 0 | ' | ' | ' |
Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 0 | 0 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 0 | 0 | ' | ' |
Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 35,289,187 | 31,810,412 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 3,067,780 | 10,750,594 | ' | ' |
Cost [Member] | ' | ' | ' | ' |
Cash | ' | ' | ' | ' |
Cash | 9,048,029 | 7,887,502 | ' | ' |
Cash equivalents | ' | ' | ' | ' |
Money market funds | 23,806,911 | 44,959,438 | ' | ' |
Cash and cash equivalents | 32,854,940 | 52,846,940 | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 91,265,906 | 70,396,681 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 7,363,273 | 25,551,349 | ' | ' |
Cost [Member] | US Treasury Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 5,004,745 | 5,009,194 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 2,995,377 | ' | ' | ' |
Cost [Member] | US Government Agencies Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 51,005,003 | 33,598,370 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | 1,301,728 | 14,807,642 | ' | ' |
Cost [Member] | Corporate Debt Securities [Member] | ' | ' | ' | ' |
Short-term investments (due within 1 year) | ' | ' | ' | ' |
Total short-term investments | 35,256,158 | 31,789,117 | ' | ' |
Long-term investments (due after 1 year through 2 years) | ' | ' | ' | ' |
Total long-term investments | $3,066,168 | $10,743,707 | ' | ' |
Investments_Details_Textual
Investments (Details Textual) (USD $) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Schedule of Trading Securities and Other Trading Assets [Line Items] | ' | ' |
Unrealized Gain on Securities | $79,258 | $58,888 |
Unrealized Loss on Securities | $19,608 | $21,342 |
Collaborations_Details_Textual
Collaborations (Details Textual) (USD $) | 1 Months Ended | 3 Months Ended | 1 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||
Apr. 30, 2012 | Mar. 31, 2014 | Mar. 31, 2013 | Aug. 31, 2013 | Mar. 31, 2014 | Apr. 30, 2012 | Apr. 30, 2012 | Apr. 30, 2012 | Dec. 31, 2012 | Apr. 30, 2012 | Apr. 30, 2012 | |
NMP [Member] | NMP [Member] | Development Milestones [Member] | Sales Based Milestones [Member] | Non Substantive Milestone [Member] | Non Substantive Milestone [Member] | Maximum [Member] | Minimum [Member] | ||||
Development Milestones [Member] | Development Milestones [Member] | ||||||||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Milestone Payments | ' | $5,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments to Acquire in Process Research and Development | 120,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Non-refundable Upfront Payments Received | 120,000,000 | ' | ' | 1,000,000 | ' | ' | ' | 5,000,000 | ' | ' | ' |
Collaboration Revenue | ' | 17,268,651 | 14,514,144 | ' | ' | ' | ' | ' | ' | ' | ' |
Deferred Revenue | ' | ' | ' | ' | 1,000,000 | ' | ' | ' | ' | ' | ' |
Potential Milestone Payments | 880,000,000 | ' | ' | 4,500,000 | ' | 380,000,000 | 500,000,000 | ' | 5,000,000 | 45,000,000 | 5,000,000 |
Maximum Eligible Amount for Milestone Payments | 875,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
License Costs | ' | 13,700,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
License and Services Revenue | ' | $3,600,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Stockholders_Equity_Deficit_De
Stockholders' Equity (Deficit) (Details) | 3 Months Ended | |
Mar. 31, 2014 | Mar. 31, 2013 | |
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] | ' | ' |
Weighted-average volatility | 102.00% | 101.00% |
Risk-free interest rate | 1.92% | 1.07% |
Weighted-average expected life (in years) | '6 years 3 months 18 days | '6 years 3 months 18 days |
Dividend yield | 0.00% | 0.00% |
Stockholders_Equity_Deficit_De1
Stockholders' Equity (Deficit) (Details 1) (USD $) | 3 Months Ended |
Mar. 31, 2014 | |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Weighted average Exercise Price, Expired during year | $0 |
Stock Option [Member] | ' |
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ' |
Options, Outstanding at January 1, 2014 | 5,246,465 |
Options, Granted during year | 856,261 |
Options, Exercised during year | -147,091 |
Options, Expired during year | 0 |
Options, Forfeited during year | -15,925 |
Options, Outstanding at March 31, 2014 | 5,939,710 |
Options, Exercisable at March 31, 2014 | 2,697,802 |
Weighted Average Exercise Price, Outstanding at January 1, 2014 | $6.76 |
Weighted Average Exercise Price, Granted during year | $11.13 |
Weighted Average Exercise Price, Exercised during year | $3.27 |
Weighted Average Exercise Price, Forfeited during year | $16.42 |
Weighted Average Exercise Price, Outstanding at March 31, 2014 | $7.45 |
Weighted Average Exercise Price, Exercisable at March 31, 2014 | $5.10 |
Weighted Average Remaining Contractual Term, Outstanding at March 31, 2014 | '7 years 7 months 6 days |
Weighted Average Remaining Contractual Term, Exercisable at March 31, 2014 | '6 years 2 months 12 days |
Aggregate Intrinsic Value, Outstanding at March 31, 2014 | $97,181,600 |
Aggregate Intrinsic Value, Exercisable at March 31, 2014 | $50,465,826 |
Stockholders_Equity_Deficit_De2
Stockholders' Equity (Deficit) (Details Textual) (USD $) | 3 Months Ended | |
In Millions, except Share data, unless otherwise specified | Mar. 31, 2014 | Dec. 31, 2013 |
Stockholders' Equity Deficit [Line Items] | ' | ' |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $20.60 | ' |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | '2 years | ' |
Restricted Stock Units (RSUs) [Member] | ' | ' |
Stockholders' Equity Deficit [Line Items] | ' | ' |
Percentage of Historical Forfeiture | 6.49% | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 270,649 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Term, Description | 'PRSUs will vest fifty percent based on the performance condition of commercial approval and fifty percent one year thereafter | ' |
Employee Benefits and Share-based Compensation | 2.7 | ' |
Equity Incentive Plan 2010 [Member] | ' | ' |
Stockholders' Equity Deficit [Line Items] | ' | ' |
Common Stock, Shares Authorized | 8,071,563 | 6,625,563 |
Equity Incentive Plan 2010 [Member] | Restricted Stock Units (RSUs) [Member] | ' | ' |
Stockholders' Equity Deficit [Line Items] | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | 196,710 | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Term, Description | 'RSUs are service-based awards that will vest and be paid in four equal installments annually beginning in February 2015 | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $11.11 | ' |
Allocated Share-based Compensation Expense | $2.10 | ' |
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term | '2 years 4 months 24 days | ' |
Income_Taxes_Details_Textual
Income Taxes (Details Textual) (USD $) | Mar. 31, 2014 |
In Millions, unless otherwise specified | |
For 2014 [Member] | ' |
Income Taxes [Line Items] | ' |
Operating Loss Carryforwards | $133.20 |
For 2015 [Member] | ' |
Income Taxes [Line Items] | ' |
Operating Loss Carryforwards | 39 |
For 2016 [Member] | ' |
Income Taxes [Line Items] | ' |
Operating Loss Carryforwards | 29.7 |
For 2017 [Member] | ' |
Income Taxes [Line Items] | ' |
Operating Loss Carryforwards | $16.80 |
Subsequent_Events_Details_Text
Subsequent Events (Details Textual) (USD $) | Mar. 31, 2014 | Dec. 31, 2013 | Apr. 02, 2014 | Jun. 30, 2014 |
In Millions, except Share data, unless otherwise specified | Subsequent Event [Member] | Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ' | ' | ' | ' |
Common Stock, Shares, Issued | 36,302,600 | 36,155,509 | 5,175,000 | ' |
Proceeds from Issuance of Common Stock | ' | ' | $101.80 | ' |
Deferred Revenue | ' | ' | ' | 45.7 |
Milestone Payments | $5 | ' | ' | ' |